Author:
Holdener Eduard E,Clavel Michel,Sessa Cristina,Huinink Wim ten Bokkel,Siegenthaler Pierre,Ludwig Christian,Klepp Otto,Renard Georgette,Decoster Genevieve,Pinedo Herbert M
Reference10 articles.
1. α-β-Triglycidyl-urazol (TGU, NSC 332488, I.N.N.: anaxirone): a new chemotherapeutic agent;Hilgard;Cancer Treat Rep,1984
2. Phase I trial of 1,2,4-triglycidylurazol (TGU, NSC 332488): a new triepoxide cytostatic agent;Hansen;Eur J Cancer Clin Oncol,1985
3. Phase I study of triglycidylurazol given on a 5-day iv schedule;Nicaise;Cancer Treat Rep,1986
4. A clinical and pharmacokinetic phase I study of 1,2,4-triglycidylurazol (TGU, NSC 332488);Cunningham;Eur J Cancer Clin Oncol,1986
5. WHO Handbook for Reporting Results of Cancer Treatment;WHO,1979